TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21912335
Drug: Sleep-inducing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-inducing medication (specific agents not detailed), administered over a 2-week period.
Study: 21912335
Drug: Polysomnography (PSG)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polysomnography (PSG) monitoring conducted for three consecutive nights each week, without medication on the first night as a baseline.
Study: 17301824
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/daily)
Study: 12825849
Drug: Menopausal status,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopausal status, prior hormone replacement therapy, and estrogen/progesterone receptor status of the breast tumors
Study: 8673189
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine (KET) 4 mg/kg with atropine sulfate 0.01 mg/kg
Study: 1883251
Drug: Nalmefene (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (2.5 mg oral dose)
Study: 3935120
Drug: Chlorpropamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (250 mg)
Study: 6416476
Drug: Insulin dependent
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dependent diabetics
Study: 27555374
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral and maxillofacial treatment with 3-monthly dental follow-ups
Study: 15374729
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of finasteride every day
Study: 15374729
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of finasteride every 3 days
Study: 19932356
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg twice a day
Study: 2684175
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (120 mg daily dose, 40 mg administered 3 times daily for 8 weeks)
Study: 28606441
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D therapy (50,000 IU of vitamin D3 intramuscularly monthly for six months)
Study: 28606441
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (distilled water, 0.25mL monthly for six months)
Study: 19894383
Drug: Compound Zhebei
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Zhebei Granules (CZG)
Study: 16380311
Drug: Psychic healing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychic healing treatment (exact dosage and duration not specified)
Study: 16380311
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and control groups (belief in psychic healing)
Study: 3698066
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg TID
Study: 30351342
Drug: Daily Intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Intake Guide (FoPL)
Study: 27538776
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intraoperative electron radiotherapy (IOERT)
Study: 24696094
Drug: Bitopertin 30
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 30 mg/d
Study: 17020438
Drug: Pregabalin (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-600 mg)
Study: 12017347
Drug: Oral eletriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eletriptan (1.5-30 mg or 30-120 mg)
Study: 12017347
Drug: Intravenous eletriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous eletriptan (1.67-50 microg/kg or 50-102 microg/kg)
Study: 12017347
Drug: Oral eletriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eletriptan doses > or = 60 mg
Study: 2182732
Drug: Single-dose trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose trimethoprim treatment
Study: 28610561
Drug: Blended care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended care (Act and Feel treatment: an eight-week web-based program based on behavioral activation with integrated monitoring of depressive symptomatology and automatized feedback)
Study: 7685221
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (activated clotting time, > 180 sec)
Study: 3319461
Drug: 5-ASA suppositories,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA suppositories, 500 mg t.i.d. for 6 weeks
Study: 31320446
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg daily
Study: 16162943
Drug: 25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/day spread containing 2.0 g of plant sterols
Study: 16162943
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment consisting of 25 g/day control spread
Study: 10319771
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion (30 ml x kg(‐1) x h(‐1))
Study: 31816446
Drug: Ustekinumab (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (130 mg intravenous induction)
Study: 31816446
Drug: Ustekinumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (90 mg subcutaneous maintenance every 8 weeks)
Study: 28372596
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus manualised psychological therapy
Study: 28372596
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus alcohol education control
Study: 20970888
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg IV midazolam
Study: 20084738
Drug: SC Johnson's
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Johnson's Autan Bayrepel Lotion
Study: 22968615
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with antibiotics
Study: 8124045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin with sulfamethoxydiazine and/or pyrimethamine
Study: 8124045
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with clindamycin alone
Study: 8124045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin and pyrimethamine
Study: 2887327
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 1 mg, intravenous administration)
Study: 29970059
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600)
Study: 29970059
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg daily)
Study: 28400148
Drug: Topical betulin
Normalized name: betulin
DrugBank: Betulin (DB16890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betulin gel (TBG) consisting of 10% birch bark extract and 90% sunflower oil
Study: 26270686
Drug: Micafungin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (100 mg/d)
Study: 24041914
Drug: Intravenous 0.5
Normalized name: immune globulin intravenous 0.5 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.5 ml Optison
Study: 24041914
Drug: Intravenous 0.5
Normalized name: immune globulin intravenous 0.5 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.5 ml placebo (5% dextrose)
Study: 11899644
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT)
Study: 1388643
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) at 150 mg daily
Study: 1388643
Drug: Cocaine doses
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine doses (0.125 to 0.5 mg/kg)
Study: 24090124
Drug: Steel infusion
Normalized name: TruSteel Infusion Set 6MM-23 inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steel infusion set
Study: 22527351
Drug: Lersivirine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 1,000 mg QD with midazolam
Study: 22527351
Drug: Lersivirine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lersivirine 1,000 mg QD with oral contraceptives (ethinylestradiol and levonorgestrel)
Study: 20113698
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil (oral administration)
Study: 17684125
Drug: 201L allele
Normalized name: Human Factor XIII (A2) homodimer (allele F13A*1B), recombinant DNA origin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201L allele of S201L (TC versus CC)
Study: 16275814
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (low, medium, and high doses ranging from 7.5 mg/d to 50.0 mg/d)
Study: 10617523
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving treatment
Study: 30905242
Drug: 1.1% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% NaF brush-on gel used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Study: 19834016
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control (target 70 to 110 mg/dL)
Study: 19834016
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (target 70 to 300 mg/dL)
Study: 12067330
Drug: IgM anti-GM1
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IgM anti-GM1 antibodies in patients with PD (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)
Study: 12067330
Drug: IgM anti-GM1
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IgM anti-GM1 antibodies in normal controls (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)
Study: 19794979
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor
Study: 26407698
Drug: 25 %
Normalized name: oxygen 25 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Study: 15202814
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily dialysis (EDD)
Study: 11840808
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg capoten at 10.00
Study: 11840808
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg capoten at 13.00
Study: 11840808
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg capoten at other hours (7.00, 16.00, 19.00, 22.00)
Study: 9949668
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg daily, increasing to 2-3 tablets based on metabolic control)
Study: 7815986
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli preparation (Mutaflor)
Study: 31761120
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for dust mite
Study: 31761120
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for latex
Study: 31761120
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for venom hypersensitivity
Study: 25925891
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of abiraterone acetate plus prednisone (AA + P)
Study: 23557454
Drug: Empowering program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empowering program (twice a week for 60 minutes over 6 weeks)
Study: 19689759
Drug: State-of-the-art conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-of-the-art conservative treatment
Study: 28090679
Drug: Prucalopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2 mg/day)
Study: 24183868
Drug: Postoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concurrent radiochemotherapy (POCRT) with paclitaxel (175 mg/m²) and cisplatin (60 mg/m²) for four cycles, plus radiotherapy (50.4 Gy/28 fractions) concurrently with the first 2 cycles of chemotherapy.
Study: 24183868
Drug: Postoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concurrent radiochemotherapy (POCRT) for patients with ≥2 pN2 lymph nodes.
Study: 21853265
Drug: Synbiotic dietary
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic dietary supplement (Lactobacillus acidophilus NCFM and lactitol, 10 g lactitol and 2×10^10 cells of probiotic bacteria, taken twice a day for 2 weeks)
Study: 30762770
Drug: Sham-acupoints acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-acupoints acupuncture and antidepressant (fluoxetine hydrochloride tablets)
Study: 25041619
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with compression therapy
Study: 15283821
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg x kg(‐1) rocuronium (group I)
Study: 15283821
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg x kg(‐1) rocuronium (group II)
Study: 3429698
Drug: Itazigrel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itazigrel (25 mg each morning for five doses)
Study: 17347074
Drug: Metoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (5 mg administered via venous cannula)
Study: 17347074
Drug: Diltiazem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (25 mg administered via venous cannula)
Study: 11871368
Drug: Red palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red palm oil (5 ml)
Study: 7408393
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin intravenously
Study: 436626
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg digoxin intravenously
Study: 7408393
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg digoxin intravenously
Study: 7408393
Drug: Single-dose kinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose kinetics
Study: 30702059
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (765 mg)
Study: 28152319
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant supplementation (Squalene 100 mg, Vitamin C 30 mg, Coenzyme Q10 10 mg, Zinc 5 mg, Beta Carotene 3.6 mg, Bioflavonoids 30 mg, Selenium 55 mcg) administered daily for 2 weeks
Study: 25749317
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A intake in hypertensive subpopulation (1732.77±962.27 µg)
Study: 25749317
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake in hypertensive subpopulation (8.13±9.71 µg)
Study: 25749317
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E intake in hypertensive subpopulation (18.79±7.84 mg)
Study: 26693033
Drug: Desvenlafaxine 50
Normalized name: desvenlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 50 mg/d
Study: 11515850
Drug: Prolonged-release granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release granules (1 packet four times daily)
Study: 11515850
Drug: Prolonged-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tablets (2 tablets four times daily)
Study: 9935253
Drug: Treatment D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D: two crushed 100-mg trovafloxacin tablets suspended in water and given through a nasogastric tube into the stomach with enteral feeding solution
Study: 8118758
Drug: Sustained-release monofluorophosphate
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release monofluorophosphate (MFP-SR) 76 mg
Study: 8118758
Drug: Plain monofluorophosphate
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain monofluorophosphate (MFP) 76 mg
Study: 17237315
Drug: Isolated isoflavone
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated isoflavone supplementation (84 mg/d)
Study: 1750594
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (patient-controlled analgesia)
Study: 10928578
Drug: Gabapentin 1800
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1800 mg per day
Study: 1569453
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous methotrexate (HD; 4 g/m2)
Study: 1569453
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous methotrexate (LD; 40 mg/m2)
Study: 3839174
Drug: morphine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.125 mg/kg)
Study: 31997237
Drug: Qixiong Zhongzi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qixiong Zhongzi Decoction (QZD) 150 mL twice a day for 12 weeks
Study: 31997237
Drug: Levocarnitine oral
Normalized name: levocarnitine Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine oral liquid 1 g twice a day for 12 weeks
Study: 31997237
Drug: Levocarnitine oral
Normalized name: levocarnitine Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine oral liquid
Study: 22052304
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with diode laser for the first two sessions and alexandrite laser for the next two sessions
Study: 22052304
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with diode and alexandrite lasers
Study: 19380259
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy (wet cupping), single application
Study: 9277426
Drug: Liquid distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid distension (100 ml)
Study: 10220634
Drug: Felodipine-metoprolol 10/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol 10/100 mg
Study: 1303482
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg
Study: 7783459
Drug: Composite acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite acupuncture treatment (acupuncture, auriculo‐acupoint pellet pressure, herbal plasters)
Study: 19244883
Drug: GTRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTRF treatment (bioabsorbable membrane and demineralized xenograft)
Study: 19244883
Drug: CAF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF treatment (control)
Study: 16652135
Drug: oral freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral freeze-dried NT 6 gm/day
Study: 8925352
Drug: Low-dose depot
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose depot haloperidol (25 mg) combined with targeted oral neuroleptics
Study: 28160351
Drug: Lithium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium monotherapy
Study: 31757519
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine lozenge used 15 minutes before cue exposure
Study: 29145890
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg metolazone single dose
Study: 29145890
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg metolazone multiple doses
Study: 29145890
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg metolazone with food effect
Study: 29145890
Drug: Metolazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (all doses)
Study: 26717214
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait therapy with the Lokomat® system
Study: 12816549
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg/day) + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Study: 12816549
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Study: 9185746
Drug: Low-dose MEG-X
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MEG-X test (50 mg lidocaine intravenously)
Study: 2866788
Drug: Azepexole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azepexole 10 mg
Study: 31119206
Drug: O6-PUFA (soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: O6-PUFA (soybean oil, 6 g/d)
Study: 31119206
Drug: O3-PUFA (fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: O3-PUFA (fish oil, 6 g/d)